What can I do about Castration-Resistant Prostate Cancer (CRPC)?

Non-metastatic Castration-Resistant Prostate Cancer (nmCRPC) is prostate cancer that shows signs of growth, even with hormone treatment (androgen deprivation treatment (ADT)). It is not found outside the prostate. nmCRPC may not cause pain or other symptoms.

Metastatic Castration-Resistant Prostate Cancer (mCRPC) means that your prostate cancer shows signs of growth, or your PSA level rises while you’re on hormone treatment. It has also been found outside the prostate. If there are symptoms from mCRPC, they depend on where the cancer has spread. Men can feel bone pain, have a hard time urinating, feel tired or weak, lose weight, or have shortness of breath. In addition, sometimes there may be no signs or symptoms at all.

TREATMENT OFFERS

New treatments offer hope for men with nmCRPC and mCRPC. They may improve the quality and length of life for men with advanced cancer.

nmCRPC Treatment Options:
- Slow Down the Growth of Cancer
  - New drugs, called apalutamide and enzalutamide, combined with ADT may help slow cancer growth
- Strengthen Bones
  - Supplemental calcium and vitamin D may help with bone strength

mCRPC Treatment Options:
- Minor or No Symptoms
  - abiraterone + prednisone
  - enzalutamide
  - docetaxel
  - sipuleucel-T
- Cancer that’s Spread to Bones
  - abiraterone + prednisone
  - enzalutamide
  - docetaxel
  - radium-223
- Didn’t Do Well with Other Treatments?
  - abiraterone + prednisone
  - enzalutamide
  - ketoconazole + steroid
  - radionuclide therapy
- Taken Docetaxel Before?
  - abiraterone + prednisone
  - cabazitaxel
  - enzalutamide
  - cabazitaxel or enzalutamide
  - radium-223 can help with bone pain

Palliative Care
- Care to manage symptoms is also an option for mCRPC

For more information about CRPC, visit the Urology Care Foundation’s website: UrologyHealth.org

Supported by an independent educational grant from Astellas and Pfizer Inc.